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Purpose. The goal of this review is to explore the role of antimicrobial 
therapeutic drug monitoring (TDM), especially in critically ill, obese, and 
older adults, with a specific focus on β-lactams and vancomycin.
Summary. The continued rise of antimicrobial resistance prompts the 
need to optimize antimicrobial dosing. The aim of TDM is to individual-
ize antimicrobial dosing to achieve antibiotic exposures associated with 
improved patient outcomes. Initially, TDM was developed to minimize ad-
verse effects during use of narrow therapeutic index agents. Today, pa-
tient and organism complexity are expanding the need for precision dosing 
through TDM services. Alterations of pharmacokinetics and pharmaco-
dynamics (PK/PD) in the critically ill, obese, and older adult populations, in 
conjunction with declining organism susceptibility, complicate attainment 
of therapeutic targets. Over the last decade, antimicrobial TDM has ex-
panded with the emergence of literature supporting β-lactam TDM and 
a shift from monitoring vancomycin trough concentrations to monitoring 
of the ratio of area under the concentration (AUC) curve to minimum in-
hibitory concentration (MIC). PK/PD experts should be at the forefront of 
implementing precision dosing practices.
Conclusion. Precision dosing through TDM is expanding and is espe-
cially important in populations with altered PK/PD, including critically ill, 
obese, and older adults. Due to wide PK/PD variability in these popula-
tions, TDM is vital to maximize antimicrobial effectiveness and decrease 
adverse event rates. However, there is still a need for studies connect-
ing TDM to patient outcomes. Providing patient-specific care through β-
lactam TDM and transitioning to vancomycin AUC/MIC monitoring may be 
challenging, but with experts at the forefront of this initiative, PK-based 
optimization of antimicrobial therapy can be achieved.
Keywords:  aged, beta-lactams, critical illness, drug monitoring, obesity, 
vancomycin
Am J Health-Syst Pharm. 2020;77:1104-1112
As the older adult population in-creases and the obesity epidemic 
continues, patients are at heightened 
risk for infection and critical illness. 
Add to the equation altered pharmaco-
kinetics/pharmacodynamics (PK/PD), 
decreasing organism susceptibility, and 
unacceptable mortality rates and alter-
native treatment approaches become es-
sential. Precision medicine provides this 
alternative and encompasses precision 
dosing through therapeutic drug moni-
toring (TDM).
TDM was introduced in the late 
1960s to minimize toxicity resulting 
from use of narrow therapeutic index 
medications. For antimicrobials, TDM 
began with aminoglycosides.1 The 
early literature in this area focused on 
the practicality of laboratory testing, 
including methodology, turnaround 
times, and accuracy of results.1 In the 
Towards precision medicine: Therapeutic drug 
monitoring–guided dosing of vancomycin and β-lactam 
antibiotics to maximize effectiveness and minimize 
toxicity
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1980s, antimicrobial TDM studies 
shifted towards identifying site-specific 
concentrations and establishing PK/PD 
indices associated with maximal clin-
ical benefits.1–4 Using these indices, in 
the 1990s clinicians began to introduce 
new dosing schemes.1,5,6 For example, 
introduction of high-dose extended-
interval aminoglycoside therapy to 
achieve desired ratios of maximum 
concentration (C
max
) to minimum in-
hibitory concentration (MIC) allowed 
for maximal drug exposure while min-
imizing adverse events.5,6 Literature 
over the last decade has redefined 
vancomycin PD targets7-11 and char-
acterized the potential for β-lactam 
TDM12-15 to enable better clinical out-
comes, especially in populations at risk 
for suboptimal antibiotic exposure.
Most antimicrobial regimens ap-
proved in clinical trials are designed 
for the “average patient.” This treat-
ment approach is not successful for all 
patients. Clinical trials typically enroll 
patients with less severe infections and 
more susceptible bacteria, which may 
necessitate lower dosages. Therefore, 
package insert–recommended dosing 
may be insufficient for more severe in-
fection types, including those caused 
by multidrug-resistant organisms, as 
well as specific patient populations ex-
cluded from trials, such as critically ill, 
obese, and older adults. TDM provides 
an opportunity to incorporate preci-
sion dosing regimens by considering 
patient-specific PK and organism vari-
ability affecting PD. Doses that ensure 
achievement of PK/PD targets are es-
pecially challenging to predict in crit-
ical illness12,16–19, obesity20-23, and older 
adult populations,24–27 making TDM ne-
cessary. Expanding antimicrobial TDM 
services is theorized to be the way of the 
future for infectious diseases, with PK/
PD experts being at the forefront of this 
initiative. The goal of this review is to 
describe the evidence for antimicrobial 
TDM in optimizing therapy, especially 
in critically ill, obese, and older adult 
populations, with a specific focus on 
β-lactams and vancomycin.
Getting started with TDM: the 
bug, the drug, and the patient. 
Variables impacting antimicrobial  PK/
PD goals can be broken down into 3 
main components: the bug, the drug, 
and the patient (Figure 1). For micro-
organisms, the primary variable is the 
MIC, defined as the lowest antimicro-
bial concentration needed to inhibit 
bacterial growth. The MIC serves as 
a crucial component in determining 
antimicrobial concentrations needed 
to achieve therapeutic effectiveness.16 
However, the MIC alone does not take 
into consideration drug concentra-
tion fluctuations observed throughout 
a dosing interval, the concentration 
achieved at the site of infection, or the 
concentration required for bactericidal 
activity.28 Rather, PD indices include 
the MIC to predict clinical outcomes. 
Specifically, PD indices describe anti-
microbial effects as time-dependent 
(as reflected by the percentage of the 
dosing interval during which the free 
unbound drug concentration is above 
the MIC [fT>MIC]), concentration-
dependent (as indicated by the ratio 




dependent with time dependencies 
(as reflected by the ratio of 24-hour 
free unbound drug concentration area 
under the curve [AUC] to MIC [fAUC/
MIC]).20,29 Achieving antibiotic-specific 
PD targets to prevent over- and under-
exposure is a vital component of TDM. 
Selection of ideal PD targets varies 
by organism and/or patient popula-
tion. For example, targeting an fAUC/
MIC value of >400 in vancomycin 
therapy is based only on data for in-
vasive Staphylococcus aureus infec-
tions (eg, pneumonia or bacteremia).30 
Additionally, variability of organism 
MIC values limits the accuracy of de-
sired PD targets.31 A single MIC reading 
can range between 1 and 2 dilutions, 
as methodology can vary by laboratory 
and laboratory technique.31 Finally, the 
last component in the equation is the 
patient. Interpatient variability in PK 
parameters underscores the challenge 
in achieving PD therapeutic goals while 
also minimizing toxicities associated 
with antimicrobial overexposures; this 
is observed in various patient popula-
tions, especially amongst critically ill, 
obese, and older adults. In combin-
ation, PK/PD parameter variability cre-
ates uncertainty and strengthens the 
argument for individualized antibiotic 
dosing recommendations.
PK/PD alterations: patient-
specific factors. Antibiotic dosing 
is determined in early-phase clinical 
trials wherein the majority of partici-
pants are often young, healthy volun-
teers with minimal PK variability.28 In 
contrast, patients with severe infections 
display increased variability in volume 
of distribution (V
d
), protein binding, 
and drug clearance.16,20,25 Key PK alter-
ations in specific patient populations, 
including critically ill, obese, and older 
adults, are further described in Table 
1.16,21,23,25 These alterations are multifac-
torial and may not be present in all pa-
tients, further decreasing predictability 
of PK/PD and supporting the use of 
TDM (Figure 1).
Critical illness. Critical illness is 
often associated with a rise in car-
diac output, which results in increased 
clearance, endothelial dysfunction, 
and capillary leak leading to excess 
extravascular fluid.16,20 These effects re-
sult in an increased V
d
 for hydrophilic 
KEY POINTS
• Therapeutic drug monitoring 
(TDM) is essential due to in-
creased patient and organism 
complexity, which leads to 
high variability in pharma-
cokinetics and pharmaco-
dynamics (PK/PD).
• Patient populations with highly 
variable PK/PD include the 
critically ill, obese, and older 
adults.
• Precision dosing of β-lactams 
and vancomycin through TDM 
is increasingly crucial for these 
patient populations to im-
prove  outcomes and minimize 
toxicities.
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antibiotics (eg, β-lactams, vancomycin, 
aminoglycosides), whereas lipophilic 
antibiotics (eg, fluoroquinolones, 
macrolides) are minimally affected.16 
Beyond fluid shifts, transcapillary escape 
of albumin results in hypoalbuminemia, 
which is reported in 40% to 50% of crit-
ically ill patients. Consequently, higher 
free drug concentrations, larger V
d
, 
and enhanced clearance occur.17,20 
For example, in healthy volunteers 
vs patients with iatrogenically in-
duced hypoalbuminemia due to use of 
ceftriaxone, a highly (85%-95%) protein-
bound antimicrobial, it was found that 
the hypoalbuminemic patients had sig-
nificantly higher median fC
max
 (107 mg/L 
vs 51 mg/L) and V
d
 (0.18 L/kg vs 0.15 L/
kg).32 Additionally, critically ill patients 
may have augmented renal clearance 
(ARC), defined by convention as cre-
atinine clearance of ≥130 mL/min/m2.19 
The cause of ARC is poorly characterized 
but thought to be related to systemic in-
flammatory response syndrome or other 
severe inflammatory conditions that can 
increase cardiac output and decrease 
vascular resistance, ultimately increasing 
renal blood flow.19 Conversely, critic-
ally ill patients are at high risk for acute 
kidney injury, adding to the complexity 
of predicting antimicrobial PK/PD.
Obesity. The number of individuals 
with obesity in the United States is ex-
pected to reach 65 million by the year 
2030.33 PK variability in obese patients 
is due to alterations in V
d
 and clear-
ance resulting from increased adipose 
tissue and lean muscle mass. First, V
d
 
Figure 1. Therapeutic drug monitoring TDM conceptual model. AKI indicates acute kidney injury; ARC, augmented renal 
clearance; Cl, clearance; CVVHD, continuous venovenous hemodialysis; ECMO, extracorporeal membrane oxygenation; 
fT>MIC, free unbound drug concentration time above minimum inhibitory concentration (MIC); fAUC/MIC, ratio of free un-
bound drug concentration area under the curve to MIC; fCmax/MIC, ratio of free peak plasma concentration to MIC; Ke, 
elimination rate constant; IV, intravenous; PK, pharmacokinetics; t1/2, half-life; Vd, volume of distribution. Note that opti-
mized drug dosing may reduce the need for TDM.
Table 1. Key Pharmacokinetic Alterations in Specific Patient Populations
Populationa Volume of Distribution Protein Binding Clearance
Critically ill adults Increased16 Decreased16 Increased or decreased16
Obese adults Increased21 No change23 Increased21
Older adults Increased or decreased25 Decreased25 Decreased25
aAlterations in pharmacokinetic parameters may vary depending on comorbidities and other patient-related factors.
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may be overestimated for hydrophilic 
antimicrobials (eg, β-lactams, vanco-
mycin, aminoglycosides)20 due to poor 
penetration into adipose tissue.21 For 
example, in a study comparing obese 
vs nonobese patients receiving vanco-
mycin, the estimated mean (SD) V
d
 was 
significantly higher in obese patients 
(74.4 [14.5] L vs 50.4 [9.3] L).22 Second, 
obese patients have increased organ 
mass, which may lead to increased 
renal blood flow, thus increasing renal 
clearance.21 Lastly, patients who have 
undergone gastric bypass surgery also 
have significant PK/PD alterations due 
to the loss of surface area for medi-
cation absorption.34 Dosing becomes 
further complicated as obese patients 
age, develop chronic kidney disease, or 
experience acute kidney injury, which 
can reduce drug clearance.35
Older adults. The older adult popu-
lation (ie, individuals 65 years of age 
or older) is projected to almost double 
by the year 2050.36 Physiologic alter-
ations in older adult patients include 
reduced gastric acid secretions, which 
affect absorption; reduced renal and 
hepatic blood flow, which slows the 
rate of clearance; and reduced serum 
protein concentrations, which in-
creases free drug concentrations.25 
For example, ertapenem PK data for 
older vs younger adult patients reveal a 
longer half-life (5.2 hours vs 3.8 hours), 
slower clearance, higher fAUC (39%), 
and higher unbound ertapenem (55.4 
mg/L vs 33.2 mg/L).26 Overexposure 
to antimicrobials in the older adult 
population puts them at increased risk 
for adverse events, and TDM can limit 
such events.
Role of therapeutic drug moni-
toring. Due to extensive PK/PD vari-
ability in these populations, leading to 
either a lack of target therapeutic ef-
fectiveness or overexposure leading 
to toxicity, precision dosing guided by 
TDM aids patients outside “normal” ex-
posure curves. Further, the presence of 
multidrug-resistant organisms or less 
susceptible organisms with elevated 
MICs may hinder the ability to achieve 
desired PD targets and highlights the 
scenario where TDM may be beneficial.
Beta-lactam TDM. Beta-lactam 
PD is defined as time-dependent killing 
(as indicated by fT>MIC).28 Recom-
mended percentage fT>MIC targets are 
40% to 50% for penicillins, 60% to 70% for 
cephalosporins, 40% for carbapenems, 
and 50% to 60% for monobactams.16,28,37 
However, in the literature these tar-
gets vary based on the β-lactam and 
organism targeted and are derived 
from animal studies, some dating ori-
ginally from the 1950s.38–41 A target of 
100% fT>MIC, as used in the BLING-I 
trial comparing continuous infusion 
vs intermittent infusion in critically ill 
patients42 and in other observational 
studies,43,44 may be more appropriate in 
an age of rising MICs. Target concen-
trations maintained above 4 times the 
MIC throughout the dosing interval (ie, 
concentrations of 100% fT>4×MIC) have 
also been described to improve out-
comes.45 Attainment of these PD targets 
for bactericidal effects depends on the 
specific pharmacokinetic and pharma-
codynamic properties of the β-lactam, 
the patient, and the infecting organism, 
thus supporting TDM.28 However, the 
desired PD targets still remain to be 
elucidated. Current β-lactam TDM 
practices are aimed at achieving 100% 
fT>MIC or 100% fT>4×MIC, but perhaps 
lower percentage targets (40% to 70%), 
as described above, are adequate. It is 
crucial that PK/PD experts begin to take 
the lead in efforts to discover the ideal 
PD target for β-lactam TDM that posi-
tively impacts patient outcomes.
The use of β-lactam TDM has pri-
marily been studied in the critically ill 
population, with limited reported ex-
perience in obese and older adult pa-
tients. Evidence is supported by known 
alterations in PK/PD. For example, 
an analysis of critically ill patients re-
ceiving β-lactams found that those 
with ARC had a trough concentration 
below the MIC 82% of the time.18 In 
addition, a prospective comparative 
study assessing critically ill severely 
obese patients (body mass index [BMI] 
of >35) vs nonobese patients (BMI of 
<30) receiving continuous-infusion 
piperacillin/tazobactam therapy found 
that measured piperacillin plasma 
concentrations were significantly lower 
for obese patients, and the percentage 
of time during which the piperacillin 
plasma concentration was above the 
target of 64 mg/L (4-fold higher than 
the MIC) was lower (64% vs 93%, P = 
0.027).15 It should be noted that assess-
ment of outcomes was dependent on 
the identified ideal PD target. However, 
this study highlighted PK/PD variability 
in this patient population. Trough con-
centrations of cefotaxime, meropenem, 
and piperacillin were also assessed in 
patients over the age of 70.46 The in-
vestigators found wide variability in 
results and concluded that only 36% of 
patients achieved a trough value above 
the desired MIC breakpoint. Therefore, 
the inability to accurately predict serum 
β-lactam concentrations in these pa-
tients emphasizes the importance of 
β-lactam TDM to ensure adequate 
exposures associated with improved 
outcomes.
TDM is also essential in preventing 
the toxicities of β-lactam overex-
posure. A retrospective analysis of TDM 
in patients treated with piperacillin, 
meropenem, or flucloxacillin found that 
patients who developed neurotoxicity 
during use of any of the 3 antibiotics and 
patients who developed nephrotoxicity 
during use of piperacillin or meropenem 
had significantly higher mean trough 
concentrations.47 The investigators de-
fined threshold trough concentrations 
associated with a 50% risk of neurotox-
icity (piperacillin C
min
 of >361.4 mg/L; 
meropenem C
min
 of >64.2 mg/L; and 
flucloxacillin C
min




>462.65 mg/L; meropenem C
min
 of >44.45 
mg/L). Another retrospective study as-
sessing septic intensive care unit (ICU) 
patients undergoing TDM during treat-
ment with meropenem, piperacillin/
tazobactam, ceftazidime, or cefepime 
found that worsening neurological 
status was associated with increased 
trough concentrations of piperacillin/
tazobactam and meropenem.48 Con-
versely, researchers who conducted a 
retrospective study evaluating critically 
ill patients receiving either conventional 
or higher-than-conventional doses of 
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meropenem or piperacillin/tazobactam, 
with dosing in both groups guided by 
TDM, concluded that there were no sig-
nificant between-group differences in 
rates of various toxicities.49 Similary, a 
single-center retrospective cohort study 
of 300 patients (a total of 403 imipenem 
plasma concentrations were measured) 
found that 5% of patients experienced 
toxicity, but those patients did not have 
higher trough concentrations than pa-
tients who did not experience toxicity.50 
These findings demonstrated the sig-
nificance of using β-lactam TDM to op-
timize dosing and minimize adverse 
effects but also indicated that validation 
of toxicity thresholds is still needed.
A recent single-center, retrospective 
cohort study of 319 patients undergoing 
cefepime TDM found that a trough 
concentration less than 7.5 mg/L would 
limit the incidence of neurotoxicity.51 
However, patients who experienced 
cefepime-associated neurotoxicity 
had a median plasma trough con-
centration of 21.6 mg/L (interquartile 
range [IQR], 17.0–28.6 mg/L.51 Another 
single-center, retrospective cohort 
study assessing 161 cefepime trough 
levels from 93 patients found that a 
threshold of less than 20 mg/L should 
be targeted to limit toxicity.52 The mean 
(SD) trough concentration among pa-
tients with toxicity was 52.2 (8.4) mg/L 
(range, 25.7–59.7 mg/L).52 More re-
search is necessary to define the ideal 
toxicity threshold for cefepime along 
with all other β-lactams. An ongoing 
prospective clinical trial, the OPTIMAL 
TDM Study (Clinicaltrials.gov iden-
tifier, NCT03790631) aims to assess 
the toxicity of cefepime, imipenem, 
meropenem, piperacillin, flucloxacillin, 
amoxicillin, and ceftazidime.
Evidence of improvement of 
other patient outcomes by means 
of β-lactam TDM remains limited; 
however, monitoring of β-lactams 
is increasingly becoming an area of 
interest. A 2015 survey of intensivists 
and infectious diseases physicians in 
France found that 21% of respondents 
monitored β-lactams at their institu-
tion.53 Another international survey, 
which targeted clinicians in 9 ICUs 
that performed β-lactam TDM, indi-
cated that piperacillin and meropenem 
were the most commonly monitored 
β-lactams (100% of units), followed by 
ceftazidime (78%), ceftriaxone (43%), 
and cefazolin (43%).54
The implications of failure to 
achieve fT>MIC targets has not been 
extensively described except by re-
searchers who conducted the Defining 
Antibiotic Levels in Intensive Care Units 
(DALI) study.12 This prospective, multi-
national study evaluated PK/PD target 
attainment with use of 8 β-lactams in 
361 critically ill patients. Of the 361 pa-
tients, 248 were treated for active infec-
tion; 50% fT>MIC was not achieved in 
approximately 16% of those patients, 
and they were 32% less likely to have 
a positive clinical outcome (odds ratio 
[OR], 0.68; 95% confidence interval [CI], 
0.52–0.91; P = 0.009). The researchers 
concluded that achieving either 50% 
fT>MIC or 100% fT>MIC was associated 
with positive outcomes (ORs of 1.02 
[95% CI, 1.01–1.04] and 1.56 [95% CI, 
1.5–2.13], respectively). However, 100% 
fT>MIC was achieved in only 60.4% of 
the patients, and the researchers’ use of 
a target of 50% fT>MIC led to potential 
overstating of the rate of target attain-
ment for patients on a cephalosporin, 
for which the recommended PD target 
is 60% to 70% fT>MIC.28 These results 
highlight the need to elucidate ideal 
PD targets and indicate that different 
targets may be needed for different 
infectious syndromes (this study con-
sidered all patients with active infec-
tions, without stratification by infection 
type). Nonetheless, the study is key in 
describing that not achieving PD targets 
can lead to poor clinical outcomes and 
supports the importance of TDM. More 
clinical outcomes data surrounding 
TDM are still needed, especially for 
obese and older adult populations.
Vancomycin TDM. Vancomycin 
is a hydrophilic antimicrobial widely 
distributed throughout body tis-
sues. It is about 55% protein bound 
and is primarily eliminated by the 
kidney.30 Consensus guidelines from 
the American Society of Health-System 
Pharmacists, Infectious Diseases 
Society of America, and Society of 
Infectious Diseases Pharmacists stated 
that vancomycin PD is best charac-
terized by AUC/MIC.30 The target for 
therapeutic effectiveness is an AUC/
MIC
24
 of ≥400. However, this AUC/MIC 
goal is based on total drug concentra-
tions, which may not be generalizable 
to patients with hypoalbuminemia. 
Additionally, the described AUC/MIC 
target only applies to invasive S. aureus 
infections, with estimates of AUC/MIC 
values based on the vancomycin MIC 
for S. aureus.30 Therefore, if estimating 
AUC alone, vancomycin exposures will 
increase as the MIC increases (eg, if the 
reported MIC is 1.5 or 2.0, the AUC tar-
gets would be 600 mg · h/L and 800 mg · 
h/L, respectively, in order to achieve an 
AUC/MIC of 400).
Although use of vancomycin trough 
levels for TDM continues, recent re-
search suggests that this is inadequate. 
In a meta-analysis assessing 14 obser-
vational cohort studies involving a total 
of 1,677 patients with S. aureus bacter-
emia, higher AUC/MIC values (≥400) 
were associated with reduced treatment 
failure, whereas higher trough concen-
trations (≥15 mg/L) were not.11 In an-
other study, modeling of vancomycin 
PK in patients with normal renal func-
tion and therapeutic AUC/MIC values 
(ie, ≥400, assuming a MIC of 1 mg/L) 
predicted that trough concentrations 
would be below the recommended 
target for serious infections (<15 mg/L) 
about 60% of the time.7 This is espe-
cially concerning because trough con-
centrations greater than 15 mg/L were 
shown to confer a 3-fold increased risk 
of nephrotoxicity in a multicenter, pro-
spective, observational trial.55 A 3-year 
prospective serial cohort study also 
determined that AUC-guided dosing 
was more likely to achieve therapeutic 
targets compared to trough-guided 
dosing, and 31% of AUCs of ≥400 
mg · h/L were associated with troughs 
of <10 mg/L and 68% with troughs of 
<15 mg/L.8 In addition, implementa-
tion of AUC/MIC as the vancomycin 
PD target leads to fewer blood samples 
overall,8 shorter durations of therapy,8 
and reduced nephrotoxicity.8,9,56 An 
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AUC
24
 threshold for AKI risk of >563 
mg · h/L was identified by classifica-
tion and regression tree (CART) ana-
lysis.9 However, prior publications have 
demonstrated that an AUC threshold 
between 600 and 1,300 mg · h/L is pre-
dictive of AKI, so there is still a need to 
determine the optimal upper limit for 
AUC/MIC for vancomycin to minimize 
toxicities.7,57,58 Results of a retrospective 
cohort analysis suggested that a daily 
AUC range of 400 to 700 mg · h/L may 
be reasonable based on findings that an 
AUC
24
 of ≥677 mg · h/L and an AUC
24-
48h
 of ≥683 mg · h/L were associated 
with higher rates of nephrotoxicity (P < 
0.05).59
Vancomycin in the critically ill.  AUC/
MIC monitoring is crucial for limiting 
nephrotoxicity and exposure in at-risk 
populations. Critically ill patients are 
often at increased risk for nephrotoxicity 
due to severity of illness, a higher likeli-
hood of administration of concomitant 
nephrotoxic agents, and the potential for 
longer durations of treatment.60,61 In add-
ition, receiving vancomycin in the ICU 
setting was found to be an independent 
risk factor for nephrotoxicity;62 although 
that association did not remain statistic-
ally significant on multivariable analysis 
(OR, 1.90; 95% CI, 0.95–3.8), this popula-
tion certainly remains at risk. Therefore, 
due to an increased risk of nephrotox-
icity, additional caution is warranted, 
and integrating AUC/MIC monitoring 
may mitigate this issue. More research 
on AUC/MIC TDM in critically ill pa-
tients is still required.
Vancomycin in obesity. Obese pa-
tients may also be at increased risk for 
nephrotoxicity due to higher doses given 
in an attempt to achieve therapeutic 
concentrations. In a retrospective cohort 
study, administration of higher vs lower 
doses of vancomycin (≥4 g vs <4 g) was 
associated with a statistically significant 
increase in nephrotoxicity, and patients 
with a total body weight of ≥101.4 kg had 
a higher incidence of nephrotoxicity.63 In 
2 different multicenter, retrospective co-
hort studies of severely ill patients with 
methicillin-resistant S. aureus (MRSA) 
bacteremia, vancomycin dosing for 
patients with a weight of >100 kg was 
found to be an independent predictor 
of nephrotoxicity by multivariable ana-
lysis.62,64 Conversely, a retrospective co-
hort analysis comparing dosing for obese 
vs lean patients found no difference in 
nephrotoxicity.65 Nonetheless, imple-
mentation of AUC/MIC monitoring is 
crucial to limit vancomycin exposure 
and toxicity. AUC/MIC monitoring in 
obese patients should be calculated with 
peak and trough concentrations or using 
Bayesian modeling, as use of a single 
trough concentration may not take into 
account total body weight and creatinine 
clearance.66
Vancomycin in older adults. Older 
patients may be at increased risk for 
nephrotoxicity due to reduced vanco-
mycin clearance resulting from impaired 
renal function. A retrospective analysis 
of 95 older adult patients (mean [SD] 
age of 82.3 [6.7] years) found that AUCs 
and trough concentrations did not cor-
relate.24 More than 30% of cases with a 
trough concentration of <15 mg/L had 
an AUC
24
 of >400 mg · h/L.24 These find-
ings did not account for the MIC but 
still justify the importance of using AUC 
to describe exposure. However, other 
data regarding the relationship between 
age and risk of vancomycin-associated 
nephrotoxicity are conflicting, with con-
comitant nephrotoxic agents playing a 
role.60,67 A recent matched cohort study, 
adjusted for risk factors including con-
comitant nephrotoxic agents, found no 
difference in the risk of AKI when com-
paring patients in 3 age groups (18-64, 
65-79, and ≥80 years).68 In opposition, 2 
different multicenter, retrospective co-
hort studies of severely ill patients with 
MRSA bacteremia found that age greater 
than 52 years and age greater than 65 
years were predictive of 2.1- and 2.6-
fold increases in the odds of nephrotox-
icity, respectively.62,64 Overall, evidence 
supporting AUC/MIC monitoring is 
increasing and is consistent with pri-
mary TDM tenets of maximizing effect-
iveness and minimizing adverse events.
Implementing TDM. Implementa -
tion of TDM practices for β-lactams 
and transitioning vancomycin TDM 
to target AUC/MIC may present sev-
eral obstacles, including cost, assay 
availability, and proper staff education. 
Due to these constraints, TDM should 
be reserved for patients with altered 
PK and/or PD (as discussed in this re-
view) and also for patients requiring 
longer courses of therapy or patients 
with difficult-to-eradicate infections 
such as infective endocarditis, vas-
cular or device-related infections, and 
osteomyelitis, as well as those with in-
fections caused by multidrug-resistant 
organisms or organisms with elevated 
MICs. If the course of therapy is an-
ticipated to extend beyond the hos-
pital stay, outpatient antibiotic therapy 
(OPAT) should also be considered.
Specific considerations for β-lactam 
TDM include the limited availability 
or lack of commercially available 
β-lactam assays due to strict US Food 
and Drug Administration (FDA) ap-
proval processes.69 Without FDA ap-
proval, institutions can collaborate 
with their laboratory team to develop 
in-house assays. When developing 
these assays, teams should focus on 
the importance of an assay with rapid 
turnaround time to maximize clinical 
relevance.70 To minimize costs, insti-
tutions may also opt for batch testing. 
Institutions with limited resources may 
opt to ship samples for testing; how-
ever, personnel need to be aware of the 
importance of freezing samples upon 
collection to avoid degradation of cer-
tain antibiotics (eg, imipenem).71 When 
results are not immediately available, 
providers should also consider the dur-
ation of therapy (eg, if results are not 
available until day 3 of therapy but only 
a 5-day course is required). Timing of 
sample collection for drug level deter-
minations and result interpretation will 
be dependent on the desired PD target. 
For example, if the goal is 50% fT>MIC, 
a sample should be collected at 50% of 
the dosing interval; if the goal is 100% 
fT>MIC, a trough concentration can 
be collected.72 If MIC concentrations 
are not yet available, the clinical break-
point for the suspected pathogen can 
be utilized while still considering the 
toxicities of overexposures.48 The type of 
infusion should also be considered, as 
intermittent, extended, and continuous 
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infusions have been shown to assist 
in PD target attainment.37 Alternative 
infusion strategies, as well as dosing 
nomograms and Bayesian software, 
can supplement β-lactam TDM. 
However, these strategies may not be 
applicable to all clinical scenarios and 
should always be implemented along 
with education.
For vancomycin, options for TDM 
may depend on the resources avail-
able at the institution. While targeting 
a trough concentration requires only 
1 serum sample and is intuitively 
simple, measuring the AUC/MIC re-
quires 2 postdose samples and some 
calculations. Advantageously, the 
2 postdose samples do not need to 
be collected at specific times, but 
2 samples are required to calculate 
patient-specific PK. For ease of im-
plementation, the first sample can be 
obtained 1 to 2 hours after the end of 
the vancomycin infusion for a peak 
level determination, and the second 
sample can be obtained towards 
the end of the dosing interval to de-
termine a value similar to a trough 
value. Once both levels are available, 
AUC calculations can be performed 
by software, home-grown Excel 
(Microsoft Corporation, Redmond, 
WA) calculations, or even an elec-
tronic medical record’s built-in calcu-
lators. The alternative to calculating 
AUC is Bayesian estimation. Software 
available for Bayesian methodology 
as well as AUC calculations has been 
previously summarized.73 Finally, 
effective implementation of both 
β-lactam TDM and an AUC/MIC PD 
target for vancomycin will require 
persistent education of all involved in 
patient care, including those without 
PK/PD expertise. Experts should be 
at the forefront of this education ini-
tiative to ensure effective rollout of 
monitoring and dosing protocols.
Conclusion
Precision dosing through TDM is 
expanding and is especially important 
in populations with altered PK/PD, 
among them the critically ill and 
and older adults. Due to wide PK/PD 
variability in these populations, TDM 
is vital to maximize antimicrobial ef-
fectiveness and decrease adverse 
event rates. However, there is still a 
need for studies connecting TDM to 
patient outcomes. Providing patient-
specific care through β-lactam TDM 
and transitioning to vancomycin 
AUC/MIC monitoring may be chal-
lenging, but with PK/PD experts at the 
forefront of this initiative, optimiza-
tion of antimicrobial therapy can be 
achieved.
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